Provided by Tiger Trade Technology Pte. Ltd.

CINGULATE INC.

7.70
+1.2118.64%
Post-market: 7.740.0359+0.47%19:59 EST
Volume:535.66K
Turnover:3.93M
Market Cap:57.34M
PE:-1.51
High:7.75
Open:6.75
Low:6.53
Close:6.49
52wk High:7.75
52wk Low:3.20
Shares:7.45M
Float Shares:7.44M
Volume Ratio:1.44
T/O Rate:7.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1005
EPS(LYR):-10.1953
ROE:-275.85%
ROA:-106.65%
PB:16.51
PE(LYR):-0.76

Loading ...

Company Profile

Company Name:
CINGULATE INC.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
13
Office Location:
1901 West 47th Place,Kansas City,Kansas,United States
Zip Code:
66205
Fax:
- -
Introduction:
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Directors

Name
Position
John A. Roberts
Chairman of the Board
Shane J. Schaffer
Chief Executive Officer and Director
Bryan Lawrence
Director
Jeffrey S. Ervin
Director
Peter J. Werth
Director

Shareholders

Name
Position
Shane J. Schaffer
Chief Executive Officer and Director
Jennifer L. Callahan
Senior Vice President,Chief Financial Officer and Secretary
Matthew Brams
Executive Vice President and Chief Medical Officer
Raul R. Silva
Executive Vice President and Chief Science Officer